Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQH2722 injection “IL-4Rα monoclonal antibody” independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), has submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center (CDE) and has been accepted for use in adults with moderate to severe atopic dermatitis (AD) where topical drug control is poor or unsuitable for treatment with topical medication.

Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQH2722 injection “IL-4Rα monoclonal antibody” independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), has submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center (CDE) and has been accepted for use in adults with moderate to severe atopic dermatitis (AD) where topical drug control is poor or unsuitable for treatment with topical medication.